Compare Wegovy vs Mounjaro Mechanisms & UK Availability
Wegovy or Mounjaro or Ozempic: UK Stock Availability Comparison
The availability landscape for weight management treatments has dramatically improved across the UK in 2024. Unlike previous supply shortages that left patients waiting months for Wegovy, EverydayMeds maintains consistent stock levels of all approved treatments including Wegovy, Mounjaro, and clarification on Ozempic's licensed indications. Our reliable supply chain partnership with Novo Nordisk ensures all five Wegovy doses remain available for immediate dispatch, whilst our Mounjaro inventory covers the complete dose escalation schedule from 2.5mg through 15mg maintenance.
The critical distinction many patients miss is that Ozempic, while containing the same semaglutide as Wegovy, is licensed exclusively for type 2 diabetes management in the UK. Promoting Ozempic for weight management constitutes off-label use, which UK prescribers cannot legally support through our platform. This leaves Wegovy and Mounjaro as the two prescription-only medicine options specifically approved by the MHRA for weight management, both requiring clinical assessment and ongoing prescriber supervision.
Wegovy or Mounjaro or Ozempic: Complete Pricing Structure
Understanding the cost implications when choosing between Wegovy or Mounjaro treatments requires examining both single pen pricing and bundle convenience options. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Mounjaro follows a different pricing structure reflecting its dual-hormone mechanism and manufacturing costs.
Our bundle options provide convenient multi-month planning rather than traditional savings models. The Intro Duo (0.25mg & 0.5mg Wegovy pens) costs £169.99, covering your first two months of dose escalation in a single order. The Progress Trio bundle (0.5mg, 1mg & 1.7mg) is priced at £369.99, ensuring seamless progression through months 2-4 of treatment. For maintenance phase patients, the Ultimate Stability Trio provides three months of 2.4mg pens for £649.99, eliminating the need for monthly reordering.
Clinical Evidence: Wegovy or Mounjaro or Ozempic Comparative Trials
The clinical evidence supporting Wegovy centres on the comprehensive STEP trial programme, with STEP 1 demonstrating average weight loss of approximately 15% at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). STEP 2 showed effectiveness in patients with type 2 diabetes, achieving around 9.6% average weight loss, whilst STEP 5 confirmed sustained results of 15.2% at two years. The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events.
Mounjaro's clinical evidence stems from the SURMOUNT trials, evaluating tirzepatide's dual GIP and GLP-1 receptor agonist mechanism. These trials cannot be directly compared to Wegovy's STEP programme due to different study designs, patient populations, and endpoint measurements. Both treatments demonstrated clinically meaningful weight loss when combined with lifestyle interventions, though individual responses vary significantly based on adherence, baseline characteristics, and concurrent medical conditions.
How Wegovy Works Compared to Mounjaro Mechanisms
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone responsible for post-meal satiety signals. This mechanism works primarily through appetite reduction centres in the brain, promoting earlier feelings of fullness during meals and potentially reducing food cravings between eating occasions. The once-weekly injection schedule supports consistent hormone levels throughout the treatment week. Mounjaro employs tirzepatide, a dual-action treatment targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual mechanism may offer additional metabolic benefits beyond appetite regulation, though both treatments require prescription-only medicine status and clinical supervision throughout use.
Ordering Process: Wegovy or Mounjaro or Ozempic Assessment
The clinical assessment process remains consistent whether you're considering Wegovy or Mounjaro, beginning with our 3-minute online questionnaire covering medical history, current medications, and weight management goals. Our UK-registered prescribers (GPhC #9012878) review each application within 24 hours for express service, or 3 working days for standard processing, ensuring appropriate treatment selection based on individual circumstances. Once approved, your chosen treatment ships via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity. The assessment covers contraindications, drug interactions, and establishes baseline measurements for ongoing monitoring. All treatments require commitment to lifestyle modifications including reduced-calorie diet and increased physical activity as mandated by MHRA licensing conditions.
Storage Considerations: Wegovy or Mounjaro or Ozempic Differences
Storage requirements present practical differences when choosing between Wegovy or Mounjaro for your weight management journey. Wegovy pens require refrigeration at 2-8°C before first use but can tolerate room temperature storage below 30°C for up to 6 weeks once removed from the fridge, making it particularly suitable for travel or flexible lifestyle schedules. Mounjaro offers 21 days of room temperature stability, which remains adequate for most travel situations but requires more careful planning for extended trips. Both treatments use pre-filled FlexTouch pen technology, eliminating the need for separate needles or complex preparation procedures. The dose escalation schedule differs between treatments, with Wegovy following a structured 16-week escalation to maintenance, whilst Mounjaro typically reaches optimal dosing over 12-16 weeks depending on individual tolerance.
UK Supply Chain Reliability for Wegovy or Mounjaro or Ozempic
The transformation of UK supply reliability for weight management treatments reflects improved manufacturing capacity and distribution partnerships throughout 2024-2025. EverydayMeds' direct relationship with pharmaceutical manufacturers ensures priority allocation during high-demand periods, preventing the supply interruptions that previously affected Wegovy availability across the UK market. Our inventory management system tracks real-time stock levels across all dose strengths, automatically triggering reorders to maintain 4-6 weeks of forward inventory coverage.
This supply chain stability becomes particularly important for patients requiring consistent dosing schedules, as interruptions can necessitate dose de-escalation and subsequent re-titration periods. Our automated reorder reminders help patients maintain treatment continuity, whilst our clinical team monitors for any potential supply chain disruptions that might affect long-term treatment planning. Both Wegovy and Mounjaro benefit from established manufacturing processes and regulatory approval, though demand patterns continue evolving as awareness of prescription weight management options increases across the UK.
Making Your Choice: Wegovy or Mounjaro or Ozempic Decision Framework
The decision between Wegovy or Mounjaro should involve consultation with qualified prescribers who can evaluate your individual medical history, treatment goals, and lifestyle factors. Both treatments are available from EverydayMeds following clinical assessment, with your prescriber helping determine which option aligns with your specific circumstances and preferences. Factors influencing choice include dosing frequency tolerance, storage convenience requirements, previous GLP-1 experience, and concurrent medical conditions requiring consideration. Remember that Ozempic remains licensed exclusively for diabetes management, making it unsuitable for weight management prescriptions through legitimate UK channels. Our clinical team provides ongoing support throughout your treatment journey, monitoring progress and adjusting approaches as needed to optimise outcomes. Start your assessment today using discount codes FIRST40 for new customers or DOSE25 for returning patients, with treatments available for next-day delivery once approved through our streamlined process at https://everydaymeds.co.uk/collections/wegovy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
